Sanofi India Q2 2026: Profit Up 19% to ₹112 Cr on 6% Sales Growth

Sanofi India Limited announced its financial results for the quarter ended June 30, 2026. The company reported a 19% increase in profits before tax and exceptional items to INR 112 crores, up from INR 94 crores in Q2 2025. Total net sales grew by 6%, driven by an 8% domestic net sales growth. The Diabetes portfolio, particularly the Insulin segment, showed strong performance with double-digit growth of 14%. Profit before tax as a percentage of net sales improved to 27% from 24%. The Board also approved the reconstitution of the Stakeholders Relationship Committee and Risk Management Committee, and noted the stepping down of the CFO and Whole Time Director.